64747-66-6

Upstream product

• 373-52-4 bromofluoromethane 
• 87199-17-5 4-formylphenylboronic acid, 
• 373-53-5 fluoroiodomethane 
• 128376-64-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde 
• 758717-04-3 4-formylbenzyl methanesulfonate 

Downstream Products

• 1313014-11-7 N-(4-fluoromethyl-benzylidene)-N'-(8-morpholin-4-yl-2-pyridin-4-yl-imidazo[1,2-b]pyridazin-6-yl)-hydrazine 
• 758717-06-5 C₅₉H₈₅FN₁₄O₁₅S₂ 

Relevant academic research and scientific papers

Monofluoroalkyl-containing compound and its preparation method and use

The invention discloses a monofluoroalkyl-containing compound and its preparation method. The preparation method comprises that in a solvent, in the presence of an alkali, an additive, a ligand and a catalyst, a compound A and a compound B undergo a suzuk

Facile Access to Fluoromethylated Arenes by Nickel-Catalyzed Cross-Coupling between Arylboronic Acids and Fluoromethyl Bromide

The nickel-catalyzed fluoromethylation of arylboronic acids was achieved with the industrial raw material fluoromethyl bromide (CH2FBr) as the coupling partner. The reaction proceeded under mild reaction conditions with high efficiency; it features the use of a low-cost nickel catalyst, synthetic simplicity, and excellent functional-group compatibility, and provides facile access to fluoromethylated biologically relevant molecules. Preliminary mechanistic studies showed that a single-electron-transfer (SET) pathway is involved in the catalytic cycle.

Palladium-Catalyzed Monofluoromethylation of Arylboronic Esters with Fluoromethyl Iodide

The first palladium-catalyzed direct monofluoromethylation of arylboronic esters to produce monofluoromethyl arenes is reported. The reaction is typically carried out at room temperature within 4 h and has a good functional group tolerance. The monofluoromethylating agent, CH2FI, was readily prepared via a halogen-exchange process.

METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS

The invention relates to conjugates of formula (V) or (VI): wherein X is -CO-NH-, -NH-, -O-, -NHCONH-, or -NHCSNH-; their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.